CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has demonstrated potential to improve prognosis in relapsed or drug-resistant ALL, though this intervention carries an increased sepsis risk that may subsequently exacerbate ALL progression [7]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.